Biomarker-Driven Lung Cancer

Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that did not progress during or following platinum-based chemoradiation.

Xiuning Le, MD, PhD, delved into the background, findings, and next steps of the SOHO-01 study.

The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Pretreatment with dexamethasone significantly reduced infusion-related reactions in patients receiving amivantamab for advanced lung cancer, according to findings from the SKIPPirr study.

Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations.

During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed with participants how they select treatment for a patient with ALK+ non–small cell lung cancer and brain metastases in the first article of a 2-part series.

An international, multicenter, first-in-human, phase 1/2 study of PFL-002/VERT-002 plans to enroll patients with NSCLC with MET alterations and expects to begin patient enrollment by the end of 2024.

Lorlatinib improved progression-free survival vs crizotinib when used as a treatment in patients ALK-positive non–small cell lung cancer.

During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, asked participants their perspectives on the use of targeted agents for patients with ALK+ non–small cell lung cancer in the second article of a 2-part series.

This case-based feature focused on oncologists at 2 virtual events who examined the development of new EGFR-targeted therapies including combinations of amivantamab with lazertinib and with chemotherapy.

A pivotal phase 2 study evaluating glecirasib for the treatment of KRAS G12C-mutated advanced non-small cell lung cancer met its primary end point with an encouraging overall response rate.

During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.

The FDA approved adjuvant alectinib following tumor resection for the treatment of patients with ALK-positive non-small cell lung cancer.

Recommendations for non–small cell lung cancer biomarker testing in early-stage disease were discussed in a presentation regarding metastatic lung cancer by Christine M. Lovly, MD, PhD.

The KRYSTAL-12 trial of adagrasib showed positive results for progression-free survival and tumor response in KRAS G12C-mutated non-small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, held a discussion on the use of biomarker testing in patients with advanced non–small cell lung cancer. This is the first of 2 articles based on this event.

The FDA has granted the supplemental new drug application of repotrectinib priority review.

The combination of avutometinib and sotorasib received FDA fast track designation for the treatment of KRAS G12C-mutant non–small cell lung cancer.

In a presentation during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow conference, Jessica Lin, MD, discussed the landscape of targeted therapies in driver mutations in non–small cell lung cancer.

Following a patient death in the phase 2 IOV-LUN-202 trial, the FDA has issued a clinical hold.

Two PD-L1 tests, SP263 and 22C3, show high agreement & effectively identify patients with early-stage non–small cell lung cancer who are likely to benefit from adjuvant atezolizumab.

The FDA did not fully approve sotorasib for the treatment of patients with KRAS G12C-mutated non–small cell lung cancer.

Anlotinib, a novel multi-targeting tyrosine kinase inhibitor, and icotinib, a first-generation EGFR TKI, demonstrated efficacy and tolerability in the first line for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer.

In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.

During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.

Repotrectinib is now an FDA-approved option for patients with ROS1- positive advanced non-small cell lung cancer.

In an interview with Targeted Oncology, Joshua Sabari, MD, discussed the rationale of studying LY3537982 in the LOXO-RAS-20001 trial and next steps for the evaluation of the agent.